Friday’s HotCopper Trends: Telix bags FDA approval, Paladin’s mine drenched | March 21, 2025

The Market Herald
03-21

The ASX has been trading flat at around 7,922 points on Friday.

Staples has been the best-performing sector, up 3%, followed by Industrials and Utilities, both up 0.5%.

Health Care has been the worst-performing, down 0.6%, followed by Information Technology, down 0.5%, and Energy, down 0.33%.

Telix Pharmaceuticals (ASX:TLX) has been the most watched on HotCopper forums today following the U.S. FDA’s approval for its New Drug Application (NDA) for Gozellix, the company’s next-generation imaging agent for prostate cancer.

Also trending is CZR Resources (ASX:CZR) after inking a deal with Robe River Joint Venture (Robe)  to divest CZR’s interest in several tenements including the Robe Mesa Iron Ore project for cash consideration of A$75 million.

Rounding out the most discussed today has been Paladin Energy (ASX:PDN) after its Langer Heinrich Mine was impacted by “unseasonal” heavy rains in Namibia.

You’re up to date – see you later for HotCopper’s Market Close.

More market news

51st State: What is Trump’s endgame with tariffs – and what will it mean for Canada?

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10